Targeted drug combo tested for Tough-to-Treat gynecologic cancers
NCT ID NCT05082025
Summary
This study tested whether combining two existing drugs, copanlisib and fulvestrant, could help control advanced endometrial or ovarian cancers that are hormone-sensitive and have specific genetic changes. The trial aimed to find a safe dose and see if the combination could shrink tumors in patients who had run out of standard treatment options. The study was terminated early after enrolling only 7 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.